JP2018509458A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509458A5 JP2018509458A5 JP2017550542A JP2017550542A JP2018509458A5 JP 2018509458 A5 JP2018509458 A5 JP 2018509458A5 JP 2017550542 A JP2017550542 A JP 2017550542A JP 2017550542 A JP2017550542 A JP 2017550542A JP 2018509458 A5 JP2018509458 A5 JP 2018509458A5
- Authority
- JP
- Japan
- Prior art keywords
- theta
- crystal
- xrpd pattern
- peaks
- dsc thermogram
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000634 powder X-ray diffraction Methods 0.000 claims 40
- 239000013078 crystal Substances 0.000 claims 39
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 26
- 238000002411 thermogravimetry Methods 0.000 claims 6
- IJFXRHURBJZNAO-UHFFFAOYSA-N 3-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1 IJFXRHURBJZNAO-UHFFFAOYSA-N 0.000 claims 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 4
- 238000001757 thermogravimetry curve Methods 0.000 claims 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical group NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims 2
- 239000005711 Benzoic acid Substances 0.000 claims 2
- 235000010233 benzoic acid Nutrition 0.000 claims 2
- 239000001530 fumaric acid Substances 0.000 claims 2
- 229960004889 salicylic acid Drugs 0.000 claims 2
- 239000004334 sorbic acid Substances 0.000 claims 2
- 235000010199 sorbic acid Nutrition 0.000 claims 2
- 229940075582 sorbic acid Drugs 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- LMQXBIARJIUMGE-LJQANCHMSA-N 3-(4-phenoxyphenyl)-1-[(3R)-1-prop-2-enylpiperidin-3-yl]pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=CC=C(C=C1)OC1=CC=CC=C1)[C@H]1CN(CCC1)CC=C LMQXBIARJIUMGE-LJQANCHMSA-N 0.000 claims 1
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 claims 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims 1
- 125000005274 4-hydroxybenzoic acid group Chemical group 0.000 claims 1
- 229960004050 aminobenzoic acid Drugs 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims 1
- 229960002598 fumaric acid Drugs 0.000 claims 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical group S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139599P | 2015-03-27 | 2015-03-27 | |
| US62/139,599 | 2015-03-27 | ||
| PCT/US2016/024321 WO2016160604A1 (en) | 2015-03-27 | 2016-03-25 | Co-crystals of a bruton's tyrosine kinase inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021009155A Division JP2021075540A (ja) | 2015-03-27 | 2021-01-22 | ブルトン型チロシンキナーゼ阻害剤の共結晶 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018509458A JP2018509458A (ja) | 2018-04-05 |
| JP2018509458A5 true JP2018509458A5 (enExample) | 2019-05-09 |
Family
ID=57006345
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550542A Pending JP2018509458A (ja) | 2015-03-27 | 2016-03-25 | ブルトン型チロシンキナーゼ阻害剤の共結晶 |
| JP2021009155A Pending JP2021075540A (ja) | 2015-03-27 | 2021-01-22 | ブルトン型チロシンキナーゼ阻害剤の共結晶 |
| JP2022111272A Pending JP2022160433A (ja) | 2015-03-27 | 2022-07-11 | ブルトン型チロシンキナーゼ阻害剤の共結晶 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021009155A Pending JP2021075540A (ja) | 2015-03-27 | 2021-01-22 | ブルトン型チロシンキナーゼ阻害剤の共結晶 |
| JP2022111272A Pending JP2022160433A (ja) | 2015-03-27 | 2022-07-11 | ブルトン型チロシンキナーゼ阻害剤の共結晶 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20180072739A1 (enExample) |
| EP (1) | EP3273962A4 (enExample) |
| JP (3) | JP2018509458A (enExample) |
| CN (1) | CN107530347A (enExample) |
| AU (1) | AU2016243122A1 (enExample) |
| BR (1) | BR112017020743A2 (enExample) |
| CA (1) | CA2981046A1 (enExample) |
| HK (2) | HK1248148A1 (enExample) |
| MA (1) | MA41828A (enExample) |
| MX (1) | MX2017012411A (enExample) |
| WO (1) | WO2016160604A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA37711A1 (fr) | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of proton tyrosine kinase inhibitor |
| WO2016156127A1 (en) | 2015-04-02 | 2016-10-06 | Ratiopharm Gmbh | Co-crystals of ibrutinib with carboxylic acids |
| US10183024B2 (en) | 2016-12-02 | 2019-01-22 | Apotex Inc. | Crystalline forms of ibrutinib |
| US12600431B2 (en) | 2017-03-17 | 2026-04-14 | Yeti Cycling, Llc | Vehicle suspension linkage |
| WO2019070698A1 (en) | 2017-10-02 | 2019-04-11 | Johnson Matthey Public Limited Company | Novel forms of ibrutinib |
| CN109776543A (zh) * | 2017-11-14 | 2019-05-21 | 上海医药工业研究院 | 依鲁替尼盐、其晶体、制备方法、药物组合物及应用 |
| CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
| WO2019195827A1 (en) | 2018-04-06 | 2019-10-10 | Johnson Matthey Public Limited Company | Novel form of ibrutinib |
| EP3575300A1 (en) | 2018-05-31 | 2019-12-04 | Apotex Inc. | Novel crystalline forms of ibrutinib |
| KR102844084B1 (ko) | 2018-06-15 | 2025-08-07 | 얀센 파마슈티카 엔브이 | 이브루티닙을 포함하는 제형/조성물 |
| US20220160713A1 (en) * | 2019-02-13 | 2022-05-26 | Prelude Therapeutics, Incorporated | Selective inhibitor of protein arginine methyltransferase 5 (prmt5) |
| DE102021104753A1 (de) | 2020-02-28 | 2021-09-02 | Yeti Cycling, Llc | Fahrzeugaufhängungs-Verbindungsaufbau mit sechs Balken und einem Antriebsstrang-Freiläufer |
| WO2021212253A1 (zh) * | 2020-04-20 | 2021-10-28 | 天津睿创康泰生物技术有限公司 | 伊布替尼葡糖糖酸内酯共晶体及其制备方法 |
| WO2022036291A1 (en) * | 2020-08-14 | 2022-02-17 | Board Of Regents, The University Of Texas System | Method of producing pharmaceutical cocrystals for additive manufacturing |
| CN114685512B (zh) * | 2020-12-31 | 2022-11-29 | 鲁南制药集团股份有限公司 | 一种伊布替尼-烟酸共晶及其制备方法 |
| WO2023242384A1 (en) | 2022-06-17 | 2023-12-21 | Krka, D.D., Novo Mesto | Crystalline form of ibrutinib |
| CN115417812B (zh) * | 2022-08-05 | 2024-04-05 | 天津大学 | 一种阿西替尼-烟酰胺共晶及其制备方法和应用 |
| CN120774923A (zh) * | 2025-07-29 | 2025-10-14 | 徐星军 | 抗癌药物伊布替尼的新晶型及其应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| ES2111065T5 (es) | 1991-04-16 | 2005-06-16 | Nippon Shinyaku Company, Limited | Procedimiento para producir una dispersion solida. |
| CZ282760B6 (cs) | 1991-11-22 | 1997-09-17 | Procter And Gamble Pharmaceuticals, Inc. | Risedronátové prostředky se zpožděným uvolňováním |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| WO1994008568A1 (fr) | 1992-10-16 | 1994-04-28 | Nippon Shinyaku Co., Ltd. | Procede pour fabriquer des matrices de cire |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| KR19990014865A (ko) | 1995-05-17 | 1999-02-25 | 피터 이. 브래이브맨 | 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들 |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6921763B2 (en) * | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| US7711492B2 (en) | 2003-09-03 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for diagnosing lymphoma types |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| EP2139487B1 (en) * | 2007-03-28 | 2015-11-11 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| EP2123626A1 (en) * | 2008-05-21 | 2009-11-25 | Laboratorios del Dr. Esteve S.A. | Co-crystals of duloxetine and co-crystal formers for the treatment of pain |
| MX2011004759A (es) * | 2011-05-04 | 2012-11-21 | Senosiain S A De C V Lab | Nuevas formas solidas de antibioticos. |
| MA37711A1 (fr) * | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
| SMT201900344T1 (it) * | 2012-09-10 | 2019-07-11 | Principia Biopharma Inc | Composti di pirazolopirimidina come inibitori di chinasi |
| GB201309085D0 (en) * | 2013-05-20 | 2013-07-03 | Redx Pharma Ltd | Compounds |
| US10253244B2 (en) * | 2013-09-04 | 2019-04-09 | Halliburton Energy Services, Inc. | Scale-inhibiting cocrystals for treatment of a subterranean formation |
| CA2922398C (en) * | 2013-09-12 | 2023-08-29 | Dana-Farber Cancer Institute, Inc. | Methods for evaluating and treating waldenstrom's macroglobulinemia |
| CN104447701B (zh) * | 2013-09-17 | 2019-03-22 | 广东东阳光药业有限公司 | 吡唑类衍生物及其用途 |
| WO2016156127A1 (en) | 2015-04-02 | 2016-10-06 | Ratiopharm Gmbh | Co-crystals of ibrutinib with carboxylic acids |
-
2016
- 2016-03-24 MA MA041828A patent/MA41828A/fr unknown
- 2016-03-25 WO PCT/US2016/024321 patent/WO2016160604A1/en not_active Ceased
- 2016-03-25 EP EP16773865.7A patent/EP3273962A4/en not_active Withdrawn
- 2016-03-25 AU AU2016243122A patent/AU2016243122A1/en not_active Abandoned
- 2016-03-25 HK HK18107890.6A patent/HK1248148A1/zh unknown
- 2016-03-25 CA CA2981046A patent/CA2981046A1/en not_active Abandoned
- 2016-03-25 BR BR112017020743A patent/BR112017020743A2/pt not_active Application Discontinuation
- 2016-03-25 MX MX2017012411A patent/MX2017012411A/es unknown
- 2016-03-25 HK HK18109250.6A patent/HK1249736A1/zh unknown
- 2016-03-25 US US15/561,624 patent/US20180072739A1/en not_active Abandoned
- 2016-03-25 CN CN201680028365.2A patent/CN107530347A/zh active Pending
- 2016-03-25 JP JP2017550542A patent/JP2018509458A/ja active Pending
-
2019
- 2019-03-01 US US16/289,936 patent/US20200031829A1/en not_active Abandoned
-
2021
- 2021-01-22 JP JP2021009155A patent/JP2021075540A/ja active Pending
- 2021-09-10 US US17/471,662 patent/US20220242868A1/en not_active Abandoned
-
2022
- 2022-07-11 JP JP2022111272A patent/JP2022160433A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018509457A5 (enExample) | ||
| Thakuria et al. | 7.03-Hydrogen bonding in molecular crystals | |
| NZ737725A (en) | Crystalline forms of a bruton’s tyrosine kinase inhibitor | |
| HRP20220371T1 (hr) | 1,3-tiazol-2-il supstituirani benzamidi | |
| JP2020128376A5 (enExample) | ||
| CR20210041A (es) | Compuestos de aminoácidos con ligadores no ramificados y métodos de uso | |
| JP2016504403A5 (enExample) | ||
| JP2016170395A5 (enExample) | ||
| JP2019532919A5 (enExample) | ||
| HRP20151299T1 (hr) | Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr | |
| RU2015143643A (ru) | Соль омекамтива мекарбила и способ ее получения | |
| JP2015522037A5 (enExample) | ||
| HRP20241789T1 (hr) | Čvrsti oblici belumosudila i soli belumosudila | |
| JP2018520999A5 (enExample) | ||
| RS52663B2 (sr) | Nova kristalna forma tiotropijum bromida i proces njene pripreme | |
| JP2016537326A5 (enExample) | ||
| JP2016108545A5 (enExample) | ||
| RU2019105794A (ru) | Кристаллогидрат соединения (2s, 3r) -изопропил 2 - (((2- (1,5-диметил-6-оксо-1,6-дигидропиридин-3-ил) -1 - ((тетрагидро-2h-пиран) -4-ил) метил) -1h-бензо [d] имидазол-5-ил) метил) амино) -3-гидроксибутаноат эдисилат | |
| RU2019112080A (ru) | Соли производного индазола и их кристаллы | |
| JP2015506987A5 (enExample) | ||
| BRPI0509720A (pt) | derivados de 4-alquil- e 4-alcanoil-piperidina substituìda e seu uso como antagonistas de neurocinina | |
| JP2016508950A5 (enExample) | ||
| PT108370A (pt) | Processo de preparação de brometo de aclidinio | |
| WO2012112841A3 (en) | [1,2,4]oxadiazol-3-yl acid salts and crystalline forms and their preparation | |
| JP2017507899A5 (enExample) |